Kantar Health Blog

  • Arnold DuBell
    Oncology Conference Insight: ECC 2015 --- Sutent® (sunitinib, Pfizer) and Votrient® (pazopanib, Novartis) are currently considered the standards of care for first-line therapy in renal cell carcinoma (RCC). However, neither drug (nor any other agents currently approved) has been able to show an overall survival (OS) benefit in clinical trials; they were approved by regulatory agencies based on a significant improvement in progression-free survival (PFS).
    Continue Reading > | Go comment! | Share
  • Arnold DuBell
    Oncology Conference Insight: ASCO 2015 --- Immunotherapy has dominated the conversation in oncology for the past several years, and the excitement still hasn’t waned at all - in fact it continues to grow. New drugs have entered development in this space, new mechanisms of action have emerged, and new tumor types have entered the focus of our attention. We have previously seen various level of evidence to support the activity of checkpoint inhibitors in melanoma, non-small cell lung cancer, renal cell carcinoma, bladder cancer, breast cancer, gastric cancer, head and neck cancer, and Hodgkin’s lymphoma. At this year’s annual meeting of the American Society of Clinical Oncology, we observed first reports of the activity of several PD-1 and PD-L1 inhibitors in multiple new tumor indications, adding to the growing body of evidence that suggests immunotherapy is closely approaching panacea status.
    Continue Reading > | Go comment! | Share
  • CheckMate? The rules of the game may be changing

    by Arnold DuBell | May 30, 2015
    Arnold DuBell
    Oncology Conference Insight: ASCO 2015 --- Non-small cell lung cancer (NSCLC) is one of the tumor types with the highest unmet need, representing the most commonly diagnosed cancer globally and one that is frequently diagnosed at an advanced stage, where prognosis is most dire. As such, NSCLC has long been a focus of significant clinical development and currently is a poster child of personalized medicine – treatment varies significantly depending on a patient’s tumor histology and their biomarker status.
    Continue Reading > | Go comment! | Share
  • Arnold DuBell
    Oncology Conference Insight: AACR 2015 --- Recent progress in the development of novel therapeutic agents to combat melanoma has been tremendous. Immune checkpoint inhibition and targeted inhibition of BRAF and MEK are two therapeutic approaches that have significantly improved survival for patients with advanced melanoma. Since 2011, the FDA has approved three checkpoint inhibitors.
    Continue Reading > | Go comment! | Share
Page